JP2008532488A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008532488A5 JP2008532488A5 JP2007554227A JP2007554227A JP2008532488A5 JP 2008532488 A5 JP2008532488 A5 JP 2008532488A5 JP 2007554227 A JP2007554227 A JP 2007554227A JP 2007554227 A JP2007554227 A JP 2007554227A JP 2008532488 A5 JP2008532488 A5 JP 2008532488A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tumor
- antibody
- carcinoma
- cell carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 32
- 210000004027 cell Anatomy 0.000 claims 29
- 201000011510 cancer Diseases 0.000 claims 18
- 239000012634 fragment Substances 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 10
- 208000003174 Brain Neoplasms Diseases 0.000 claims 8
- 208000005243 Chondrosarcoma Diseases 0.000 claims 8
- 206010009944 Colon cancer Diseases 0.000 claims 8
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 8
- 206010039491 Sarcoma Diseases 0.000 claims 8
- 208000037819 metastatic cancer Diseases 0.000 claims 8
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 8
- 208000008732 thymoma Diseases 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 201000001441 melanoma Diseases 0.000 claims 6
- 206010024612 Lipoma Diseases 0.000 claims 5
- 208000009956 adenocarcinoma Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 208000030507 AIDS Diseases 0.000 claims 4
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 claims 4
- 208000008884 Aneurysmal Bone Cysts Diseases 0.000 claims 4
- 206010003571 Astrocytoma Diseases 0.000 claims 4
- 206010004593 Bile duct cancer Diseases 0.000 claims 4
- 208000019838 Blood disease Diseases 0.000 claims 4
- 206010005949 Bone cancer Diseases 0.000 claims 4
- 208000018084 Bone neoplasm Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 208000001843 Carotid Body Tumor Diseases 0.000 claims 4
- 208000037211 Carotid body tumour Diseases 0.000 claims 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims 4
- 201000009047 Chordoma Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 4
- 206010014733 Endometrial cancer Diseases 0.000 claims 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 4
- 206010014967 Ependymoma Diseases 0.000 claims 4
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 4
- 208000021309 Germ cell tumor Diseases 0.000 claims 4
- 208000009164 Islet Cell Adenoma Diseases 0.000 claims 4
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 208000000172 Medulloblastoma Diseases 0.000 claims 4
- 206010068116 Metastatic uterine cancer Diseases 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 4
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 4
- 206010029260 Neuroblastoma Diseases 0.000 claims 4
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 4
- 206010033963 Parathyroid tumour Diseases 0.000 claims 4
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims 4
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 4
- 206010057644 Testis cancer Diseases 0.000 claims 4
- 201000009365 Thymic carcinoma Diseases 0.000 claims 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 4
- 208000026900 bile duct neoplasm Diseases 0.000 claims 4
- 210000004556 brain Anatomy 0.000 claims 4
- 201000010881 cervical cancer Diseases 0.000 claims 4
- 208000019065 cervical carcinoma Diseases 0.000 claims 4
- 208000011654 childhood malignant neoplasm Diseases 0.000 claims 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 4
- 208000009060 clear cell adenocarcinoma Diseases 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 210000001953 common bile duct Anatomy 0.000 claims 4
- 201000011523 endocrine gland cancer Diseases 0.000 claims 4
- 201000003914 endometrial carcinoma Diseases 0.000 claims 4
- 230000003352 fibrogenic effect Effects 0.000 claims 4
- 210000000232 gallbladder Anatomy 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 208000003884 gestational trophoblastic disease Diseases 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 201000010536 head and neck cancer Diseases 0.000 claims 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims 4
- 208000014951 hematologic disease Diseases 0.000 claims 4
- 208000018706 hematopoietic system disease Diseases 0.000 claims 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 4
- 201000002529 islet cell tumor Diseases 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 208000003849 large cell carcinoma Diseases 0.000 claims 4
- 201000010260 leiomyoma Diseases 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 201000005252 lipomatous cancer Diseases 0.000 claims 4
- 206010024627 liposarcoma Diseases 0.000 claims 4
- 201000007270 liver cancer Diseases 0.000 claims 4
- 208000014018 liver neoplasm Diseases 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 239000003550 marker Substances 0.000 claims 4
- 230000001394 metastastic effect Effects 0.000 claims 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims 4
- 208000023833 nerve sheath neoplasm Diseases 0.000 claims 4
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 4
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 4
- 230000011164 ossification Effects 0.000 claims 4
- 201000008968 osteosarcoma Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 claims 4
- 201000010279 papillary renal cell carcinoma Diseases 0.000 claims 4
- 208000028591 pheochromocytoma Diseases 0.000 claims 4
- 208000010916 pituitary tumor Diseases 0.000 claims 4
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 4
- 201000000849 skin cancer Diseases 0.000 claims 4
- 208000000649 small cell carcinoma Diseases 0.000 claims 4
- 201000011096 spinal cancer Diseases 0.000 claims 4
- 208000014618 spinal cord cancer Diseases 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 206010042863 synovial sarcoma Diseases 0.000 claims 4
- 201000003120 testicular cancer Diseases 0.000 claims 4
- 210000001685 thyroid gland Anatomy 0.000 claims 4
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 4
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 4
- 208000017997 tumor of parathyroid gland Diseases 0.000 claims 4
- 230000002861 ventricular Effects 0.000 claims 4
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 208000000035 Osteochondroma Diseases 0.000 claims 3
- 208000008383 Wilms tumor Diseases 0.000 claims 3
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 208000012080 benign lipomatous neoplasm Diseases 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 230000004761 fibrosis Effects 0.000 claims 3
- 208000006359 hepatoblastoma Diseases 0.000 claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 3
- 210000004153 islets of langerhan Anatomy 0.000 claims 3
- 208000022013 kidney Wilms tumor Diseases 0.000 claims 3
- 206010027191 meningioma Diseases 0.000 claims 3
- 201000008026 nephroblastoma Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000025443 tumor of adipose tissue Diseases 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 206010053717 Fibrous histiocytoma Diseases 0.000 claims 2
- 201000005969 Uveal melanoma Diseases 0.000 claims 2
- 208000001119 benign fibrous histiocytoma Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 201000010103 fibrous dysplasia Diseases 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 208000001783 Adamantinoma Diseases 0.000 claims 1
- 201000005262 Chondroma Diseases 0.000 claims 1
- 208000013558 Developmental Bone disease Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 241000233855 Orchidaceae Species 0.000 claims 1
- 206010072610 Skeletal dysplasia Diseases 0.000 claims 1
- 235000009754 Vitis X bourquina Nutrition 0.000 claims 1
- 235000012333 Vitis X labruscana Nutrition 0.000 claims 1
- 240000006365 Vitis vinifera Species 0.000 claims 1
- 235000014787 Vitis vinifera Nutrition 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 208000008524 alveolar soft part sarcoma Diseases 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64997905P | 2005-02-03 | 2005-02-03 | |
| US60/649,979 | 2005-02-03 | ||
| PCT/US2006/003775 WO2006084092A2 (en) | 2005-02-03 | 2006-02-03 | Antibodies to oncostatin m receptor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008532488A JP2008532488A (ja) | 2008-08-21 |
| JP2008532488A5 true JP2008532488A5 (enExample) | 2009-03-19 |
| JP5328156B2 JP5328156B2 (ja) | 2013-10-30 |
Family
ID=36777945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007554227A Expired - Fee Related JP5328156B2 (ja) | 2005-02-03 | 2006-02-03 | オンコスタチンｍレセプターに対する抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7572896B2 (enExample) |
| EP (1) | EP1846455A4 (enExample) |
| JP (1) | JP5328156B2 (enExample) |
| AU (1) | AU2006210606B2 (enExample) |
| CA (1) | CA2597171A1 (enExample) |
| WO (1) | WO2006084092A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2109668A4 (en) | 2007-01-22 | 2011-10-05 | Macrogenics West Inc | HUMAN CANCER STEM CELLS |
| PE20090321A1 (es) | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
| JP5785490B2 (ja) | 2008-04-02 | 2015-09-30 | マクロジェニクス，インコーポレーテッド | Ｂｃｒ複合体特異的抗体およびその使用方法 |
| ES2342529B1 (es) | 2008-10-07 | 2011-05-11 | Proyecto De Biomedicina Cima, S.L. | Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas. |
| ES2733067T3 (es) | 2008-12-19 | 2019-11-27 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
| EP2258723A1 (en) * | 2009-06-02 | 2010-12-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Treatment of oncostatin M receptor ß mediated heart failure |
| US20120308517A1 (en) | 2010-02-09 | 2012-12-06 | Digna Biotech, S.L. | Compositions for the treatment of infectious and tumoural diseases |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| PH12018501083A1 (en) | 2010-03-04 | 2019-02-18 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| MX339622B (es) | 2010-08-02 | 2016-06-02 | Macrogenics Inc | Diacuerpos covalentes y sus usos. |
| CA2814652C (en) | 2010-10-13 | 2021-05-18 | Janssen Biotech, Inc. | Human oncostatin m antibodies and methods of use |
| KR101801980B1 (ko) | 2011-04-27 | 2017-12-29 | 사회복지법인 삼성생명공익재단 | 중추신경계 림프종 진단용 조성물 및 이를 이용한 중추신경계 림프종 진단 키트 |
| EA201391753A1 (ru) | 2011-05-21 | 2014-08-29 | Макродженикс, Инк. | Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке |
| WO2013168829A1 (en) * | 2012-05-11 | 2013-11-14 | Wakayama Medical University | Anti oncostatin m receptor beta antibody |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| SG11201508829QA (en) * | 2013-05-30 | 2015-12-30 | Biogen Ma Inc | Oncostatin m receptor antigen binding proteins |
| US9550828B2 (en) | 2013-09-05 | 2017-01-24 | Boise State University | Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders |
| SG10201913680PA (en) | 2014-05-29 | 2020-03-30 | Macrogenics Inc | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
| MX2017009695A (es) | 2015-01-29 | 2018-04-10 | Univ Oxford Innovation Ltd | Objetivo terapeutico y biomarcador en enfermedad inflamatoria intestinal (ibd). |
| AU2016298227B9 (en) | 2015-07-30 | 2019-10-31 | Macrogenics, Inc. | PD-1-binding molecules and methods of use thereof |
| JP6955507B2 (ja) | 2015-12-14 | 2021-10-27 | マクロジェニクス，インコーポレーテッド | Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法 |
| CA3020864A1 (en) | 2016-04-15 | 2017-10-19 | Macrogenics, Inc. | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof |
| JP7132232B2 (ja) | 2017-02-24 | 2022-09-06 | マクロジェニクス，インコーポレーテッド | Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用 |
| JP2021505637A (ja) | 2017-12-12 | 2021-02-18 | マクロジェニクス，インコーポレーテッド | 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用 |
| SG11202007572VA (en) | 2018-02-15 | 2020-09-29 | Macrogenics Inc | Variant cd3-binding domains and their use in combination therapies for the treatment of disease |
| US11633457B2 (en) | 2019-04-11 | 2023-04-25 | Boise State University | Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use |
| TW202607038A (zh) | 2020-10-19 | 2026-02-16 | 美商碩騰服務公司 | 犬及貓抑瘤素Ｍ受體β之抗體及其用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3862925A (en) | 1973-07-05 | 1975-01-28 | American Home Prod | Preparation of somatotropin release inhibiting factor and intermediates therefor |
| US3842067A (en) | 1973-07-27 | 1974-10-15 | American Home Prod | Synthesis of(des-asn5)-srif and intermediates |
| JPS5726506B2 (enExample) | 1974-03-08 | 1982-06-04 | ||
| US4105603A (en) | 1977-03-28 | 1978-08-08 | The Salk Institute For Biological Studies | Peptides which effect release of hormones |
| USRE30548E (en) | 1979-08-31 | 1981-03-17 | The Salk Institute For Biological Studies | Peptides which effect release of hormones |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5681930A (en) * | 1985-12-20 | 1997-10-28 | Bristol-Myers Squibb Company | Anti-oncostatin M monoclonal antibodies |
| US5552391A (en) | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US6787153B1 (en) * | 1991-06-28 | 2004-09-07 | Mitsubishi Chemical Corporation | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US5532159A (en) | 1994-04-01 | 1996-07-02 | The Ohio State University | Monoclonal antibody to canine placental oncofetal protein for detecting cancer |
| US5783672A (en) * | 1994-05-26 | 1998-07-21 | Immunex Corporation | Receptor for oncostatin M |
| AU3272695A (en) | 1994-08-12 | 1996-03-07 | Immunomedics Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| US6054551A (en) * | 1998-07-14 | 2000-04-25 | Eastman Chemical Company | Polyester comprising a residue of isophthalic acid, terephthalic acid, ethylene glycol and an aromatic diol derivative |
| US6406840B1 (en) | 1999-12-17 | 2002-06-18 | Biomosaic Systems, Inc. | Cell arrays and the uses thereof |
| US6541225B1 (en) | 2000-01-26 | 2003-04-01 | Raven Biotechnologies, Inc. | Methods and compositions for generating human monoclonal antibodies |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| WO2003072068A2 (en) * | 2002-02-27 | 2003-09-04 | University Of South Carolina | Targeted immunotherapy of acute lymphoblastic leukemia (all) |
| JP4803789B2 (ja) * | 2004-02-03 | 2011-10-26 | 独立行政法人科学技術振興機構 | 疼痛を処置するための薬学的組成物 |
-
2006
- 2006-02-03 WO PCT/US2006/003775 patent/WO2006084092A2/en not_active Ceased
- 2006-02-03 CA CA002597171A patent/CA2597171A1/en not_active Abandoned
- 2006-02-03 JP JP2007554227A patent/JP5328156B2/ja not_active Expired - Fee Related
- 2006-02-03 US US11/346,812 patent/US7572896B2/en not_active Expired - Fee Related
- 2006-02-03 AU AU2006210606A patent/AU2006210606B2/en not_active Ceased
- 2006-02-03 EP EP06734254A patent/EP1846455A4/en not_active Withdrawn
-
2009
- 2009-07-02 US US12/497,439 patent/US8216578B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008529494A5 (enExample) | ||
| JP2010508847A5 (enExample) | ||
| JP2005532050A5 (enExample) | ||
| JP2010110329A5 (enExample) | ||
| TWI526223B (zh) | 人化ａｘｌ抗體類 | |
| US9695250B2 (en) | Pharmaceutical compositions with resistance to soluble CEA | |
| CN102939306B (zh) | 用于治疗癌症的人源化抗cxcr4抗体 | |
| JP2009297037A5 (enExample) | ||
| JP2010510809A5 (enExample) | ||
| CN113330034A (zh) | 针对B7-H3的IgV结构域的单克隆抗体及其用途 | |
| JP2013529059A5 (enExample) | ||
| JP2005538701A5 (enExample) | ||
| TW201909926A (zh) | Ｂ７ｈ３抗體－藥物偶聯物及其醫藥用途 | |
| CN121159691A (zh) | 间皮素结合蛋白质 | |
| JP2008526256A5 (enExample) | ||
| JP2007536932A5 (enExample) | ||
| JP6113933B1 (ja) | 繊維芽細胞増殖因子受容体３（ｆｇｆｒ３）に対する化合物および治療的使用 | |
| JP2010533498A5 (enExample) | ||
| JP2008508858A5 (enExample) | ||
| JP2007532139A5 (enExample) | ||
| NZ597067A (en) | Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer | |
| RU2012126138A (ru) | Специфические связывающие агенты против в7-н1 | |
| JP2013227339A5 (enExample) | ||
| JP2010518820A5 (enExample) | ||
| JP2011130770A5 (enExample) |